Horizon Investment Services LLC increased its stake in shares of Phibro Animal Health Corporation (NASDAQ:PAHC – Free Report) by 241.3% during the fourth quarter, HoldingsChannel reports. The fund owned 33,241 shares of the company’s stock after acquiring an additional 23,501 shares during the quarter. Horizon Investment Services LLC’s holdings in Phibro Animal Health were worth $1,242,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently bought and sold shares of PAHC. 1620 Investment Advisors Inc. raised its stake in Phibro Animal Health by 77.4% during the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after purchasing an additional 295 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after purchasing an additional 386 shares during the period. Rothschild Investment LLC increased its position in shares of Phibro Animal Health by 2,500.0% during the fourth quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after purchasing an additional 1,000 shares during the period. Hughes Financial Services LLC bought a new stake in shares of Phibro Animal Health during the third quarter valued at approximately $40,000. Finally, iSAM Funds UK Ltd bought a new stake in shares of Phibro Animal Health during the third quarter valued at approximately $61,000. 99.34% of the stock is currently owned by institutional investors and hedge funds.
Phibro Animal Health Price Performance
Shares of PAHC stock opened at $31.53 on Friday. The stock’s fifty day simple moving average is $43.88 and its 200 day simple moving average is $44.77. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of 13.53, a P/E/G ratio of 0.48 and a beta of 0.46. Phibro Animal Health Corporation has a one year low of $23.57 and a one year high of $60.08.
Phibro Animal Health Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd will be paid a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 1.5%. Phibro Animal Health’s payout ratio is currently 20.60%.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on PAHC. Citigroup lowered their price objective on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Finally, Weiss Ratings lowered Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Phibro Animal Health currently has a consensus rating of “Hold” and an average price target of $38.80.
Read Our Latest Stock Report on Phibro Animal Health
Key Phibro Animal Health News
Here are the key news stories impacting Phibro Animal Health this week:
- Positive Sentiment: Zacks Research raised its earnings estimates for Phibro Animal Health across several periods, including FY2026 to $3.05 EPS, FY2027 to $3.18 EPS, and FY2028 to $3.35 EPS, signaling a more constructive view of the company’s earnings power.
- Positive Sentiment: Near-term estimates were also nudged higher, including Q4 2026 to $0.69 EPS, Q1 2027 to $0.79 EPS, Q2 2027 to $0.85 EPS, Q3 2027 to $0.76 EPS, and Q1 2028/Q3 2028 to $0.82 EPS each, which may support investor confidence in execution.
- Neutral Sentiment: Zacks Research kept a Hold rating on PAHC, so the revisions are supportive but not a strong bullish upgrade.
- Neutral Sentiment: The stock still trades well below its 50-day and 200-day moving averages, so the shares remain in a weaker technical position despite the analyst optimism.
Insider Buying and Selling
In other Phibro Animal Health news, CEO Jack Bendheim sold 10,560 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $52.68, for a total value of $556,300.80. Following the transaction, the chief executive officer owned 80,360 shares of the company’s stock, valued at approximately $4,233,364.80. The trade was a 11.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 69,648 shares of company stock valued at $3,759,028 over the last quarter. 50.13% of the stock is currently owned by insiders.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Featured Stories
- Five stocks we like better than Phibro Animal Health
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Want to see what other hedge funds are holding PAHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phibro Animal Health Corporation (NASDAQ:PAHC – Free Report).
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
